What are the indications, dosing regimen, and contraindications for Paxlovid (nirmatrelvir/ritonavir) in non‑hospitalized COVID‑19 patients?

Paxlovid (Nirmatrelvir/Ritonavir) for COVID-19

For non-hospitalized COVID-19 patients at high risk of progression to severe disease, strongly recommend nirmatrelvir/ritonavir 300 mg/100 mg orally twice daily for 5 days, initiated within 5 days of symptom onset. 1, 2

Indications

High-risk patients with non-severe COVID-19 (strong recommendation) 1:

• High certainty evidence shows important reduction in hospitalization (89% relative risk reduction) and moderate certainty for survival benefit 3
• Must be within 5 days of symptom onset 2
• Reduces hospitalization from 7% to 0.77% with zero deaths in treatment group 3

Moderate-risk patients (conditional recommendation) 1:

• High certainty of hospitalization reduction, though smaller than high-risk patients
• Consider when drug interactions can be managed appropriately

Low-risk patients: Recommend against use 1 - trivial benefits do not justify cost and drug interaction risks

Dosing Regimen

Standard Dosing 2:

• 300 mg nirmatrelvir (two 150 mg tablets) + 100 mg ritonavir (one 100 mg tablet)
• Twice daily for 5 days
• Can be taken with or without food
• Nirmatrelvir MUST be co-administered with ritonavir

Renal Dose Adjustment 1, 2:

• eGFR 30-59 mL/min: Reduce to 150 mg nirmatrelvir + 100 mg ritonavir twice daily for 5 days
• eGFR <30 mL/min: Not recommended per FDA label 2, though recent data suggests 150 mg/100 mg once daily may be safe 4

Hepatic Impairment 2:

• Not recommended in severe hepatic impairment (Child-Pugh Class C)

Contraindications

Absolute Contraindications 2:

Hypersensitivity: History of clinically significant reactions to nirmatrelvir or ritonavir (including anaphylaxis, toxic epidermal necrolysis, Stevens-Johnson syndrome)

Drug interactions - Co-administration contraindicated with:

• Drugs highly dependent on CYP3A for clearance where elevated concentrations cause serious/life-threatening reactions
• Potent CYP3A inducers (may cause loss of virologic response)

Critical Drug Interaction Considerations 1, 5:

Ritonavir is a potent CYP3A4 inhibitor - causes significant drug interactions during treatment and several days after completion. Before prescribing, you must:

1. Review ALL patient medications using Liverpool COVID-19 drug interaction tool 1
2. Determine if comedications require dose adjustment, temporary discontinuation, or additional monitoring
3. Weigh benefit of reducing hospitalization/death against manageable drug interaction risks

Common problematic interactions include certain statins, anticoagulants, immunosuppressants, antiarrhythmics, and sedatives 5

Special Populations

Pregnancy and breastfeeding 1:

• Represents an option to reduce disease progression
• No reports of serious adverse reactions in WHO Vigibase
• Uncertainty remains but benefits likely outweigh theoretical risks in high-risk patients

Vaccinated patients 6:

• Still effective: 45% relative risk reduction in ER visits, hospitalization, or death
• Reduces multisystem symptoms and complications including lower respiratory tract infections and cardiac arrhythmias

HIV-positive patients 2:

• Risk of developing HIV-1 protease inhibitor resistance in uncontrolled/undiagnosed HIV-1 infection
• Use with caution and ensure HIV viral suppression

Common Adverse Effects 1, 2, 3:

• Dysgeusia (altered taste): 5.6% vs 0.3% placebo - significantly more common with nirmatrelvir/ritonavir 3, 7
• Diarrhea: 3.1% vs 1.6% placebo
• Hepatotoxicity: Monitor for transaminase elevations, clinical hepatitis 2
• No increase in adverse events leading to discontinuation compared to placebo (high certainty) 1

Key Clinical Pearls

Timing is critical: Efficacy demonstrated only when started within 5 days of symptom onset 1, 2

Not for prevention: Not approved for pre- or post-exposure prophylaxis 2

Do not combine antivirals: No evidence supporting combination with other COVID-19 antivirals 1

Symptom resolution: May not impact time to symptom resolution (low certainty) 1 - primary benefit is preventing progression to severe disease

Rebound phenomenon: Small percentage (6.8%) may seek medical care after treatment; risk factors include female sex, myocardial infarction history, chronic lung disease, and complicated diabetes 8

Resource allocation: When supply is limited, prioritize high-risk over moderate-risk patients 1